Literature DB >> 7948303

Desmopressin (DDAVP) and hemostasis.

S Lethagen1.   

Abstract

Desmopressin is a widely used hemostatic drug. It is a synthetic analogue of the natural hormone vasopressin, but, in contrast to vasopressin, it has no pressor activity. The effect is immediate, with two- to sixfold increases in the plasma concentrations of coagulation factor VIII, on Willebrand factor, and tissue plasminogen activator, and increases in platelet adhesiveness of comparable magnitude. Desmopressin is used in patients with mild hemophilia A, von Willebrand's disease, congenital platelet dysfunction, or acquired platelet dysfunction due to uremia or intake of such drugs as aspirin. It may also be used to reduce surgical blood loss in patients without known bleeding diathesis. Optimal hemostatic effect is achieved with a dosage of 0.3 micrograms/kg given intravenously. Other routes of administration are subcutaneous injection or intranasal spray. The latter proved to be efficient for home treatment of patients with bleeding disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7948303     DOI: 10.1007/bf02215950

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  95 in total

1.  Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis.

Authors:  W D Lazenby; I Russo; B J Zadeh; J A Zelano; W Ko; C C Lynch; O W Isom; K H Krieger
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

2.  Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.

Authors:  S Lethagen; A S Harris; I M Nilsson
Journal:  Blut       Date:  1990-03

3.  A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery.

Authors:  T Hackmann; R D Gascoyne; S C Naiman; G H Growe; L D Burchill; W R Jamieson; S B Sheps; M T Schechter; G E Townsend
Journal:  N Engl J Med       Date:  1989-11-23       Impact factor: 91.245

4.  The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification.

Authors:  P D Mongan; M P Hosking
Journal:  Anesthesiology       Date:  1992-07       Impact factor: 7.892

5.  The effect of DDAVP and placebo on platelet function and prolonged bleeding time induced by oral acetyl salicylic acid intake in healthy volunteers.

Authors:  S Lethagen; P Rugarn
Journal:  Thromb Haemost       Date:  1992-01-23       Impact factor: 5.249

6.  DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times.

Authors:  G E Marti; M E Rick; J Sidbury; H R Gralnick
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

7.  Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man.

Authors:  J D Cash; A M Gader; J da Costa
Journal:  Br J Haematol       Date:  1974-06       Impact factor: 6.998

8.  Water intoxication in infants caused by the urine concentration test with vasopressin analogue (DDAVP).

Authors:  O Koskimies; J Pylkkänen; J Vilska
Journal:  Acta Paediatr Scand       Date:  1984-01

9.  Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms.

Authors:  S Lethagen; P Rugarn; M Aberg; I M Nilsson
Journal:  Acta Chir Scand       Date:  1990-09

10.  Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery.

Authors:  J C Horrow; D F Van Riper; M D Strong; I Brodsky; J L Parmet
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

View more
  7 in total

1.  Intracellular trafficking of factor VIII to von Willebrand factor storage granules.

Authors:  J B Rosenberg; P A Foster; R J Kaufman; E A Vokac; M Moussalli; P A Kroner; R R Montgomery
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

Review 2.  [Therapeutic options for perioperatively acquired platelet dysfunctions].

Authors:  C F Weber; A C Schneider; T Kirschning; C Hofstetter; K Zacharowski; K Görlinger
Journal:  Anaesthesist       Date:  2009-09       Impact factor: 1.041

3.  Desmopressin acetate in intracranial haemorrhage.

Authors:  Thomas Kapapa; Stefan Röhrer; Sabine Struve; Matthias Petscher; Ralph König; Christian Rainer Wirtz; Dieter Woischneck
Journal:  Neurol Res Int       Date:  2014-12-23

4.  Stroke Classification: Critical Role of Unusually Large von Willebrand Factor Multimers and Tissue Factor on Clinical Phenotypes Based on Novel "Two-Path Unifying Theory" of Hemostasis.

Authors:  Jae C Chang
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 5.  Point-of-care coagulation management in intensive care medicine.

Authors:  Patrick Meybohm; Kai Zacharowski; Christian F Weber
Journal:  Crit Care       Date:  2013-03-19       Impact factor: 9.097

Review 6.  Clinical review: Traumatic brain injury in patients receiving antiplatelet medication.

Authors:  Christopher Beynon; Daniel N Hertle; Andreas W Unterberg; Oliver W Sakowitz
Journal:  Crit Care       Date:  2012-07-26       Impact factor: 9.097

7.  Assay of Desmopressin Acetate in Nasal Spray: Development of Validated Pre Column HPLC-Fluorescence Method.

Authors:  Neeraj Upmanyu; Pawan Kumar Porwal
Journal:  Adv Pharm Bull       Date:  2017-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.